NCT00190268View on ClinicalTrials.gov

Efficacy of 3,4-DAP in Fatigue Associated With Multiple Sclerosis

PHASE3CompletedINTERVENTIONAL
Enrollment

126

Participants

Timeline

Start Date

February 28, 2005

Primary Completion Date

June 30, 2008

Study Completion Date

June 30, 2008

Conditions
Multiple Sclerosis
Interventions
DRUG

3,4-diaminopyridine

3,4-diaminopyridine

Trial Locations (4)

35000

Pontchaillou Hospital, Rennes

75013

Pitié Salpetriere Hospital, Paris

75020

Tenon Hospital, Paris

94010

Henri Mondor Hospital, Créteil

All Listed Sponsors
lead

Assistance Publique - Hôpitaux de Paris

OTHER

NCT00190268 - Efficacy of 3,4-DAP in Fatigue Associated With Multiple Sclerosis | Biotech Hunter | Biotech Hunter